Abstract 3 0
The regulated secretory trafficking of neosynthesized transmembrane receptors is 3 1 particularly challenging to investigate as it is under-represented at steady state compared to 3 2 the abundance of the other trafficking routes. Here, we combined the retention using 3 3 selective hook (RUSH) system to a CRISPR/Cas9 gene editing approach (eRUSH) to 3 4 identify molecular players involved in the trafficking of neosynthesized Transferrin Receptor 3 5 (TfR) en route to the plasma membrane (PM). TfR-eRUSH monoclonal cells expressing 3 6 endogenous, ER-retainable and fluorescent TfR were engineered and characterized. 3 7
Spatiotemporal quantitative proteomics of TfR-eRUSH cells allowed the identification of 3 8 molecular partners associated with TfR-containing membranes and provided a 3 9 comprehensive list of potential regulators, co-trafficking cargos, and enriched pathways. 4 0 Furthermore, we chose to focus our attention on the Rab GTPase family members for their 4 1 function as vesicle trafficking regulators and performed a Rab-targeted siRNA screen that we 4 2 correlated to our proteomics data. Unexpectedly, we identified Rab7-harboring vesicles as 4 3 an intermediate compartment of the Golgi-to-PM transport of the neosynthetic TfR. These 4 4 vesicles did not exhibit degradative properties and were not associated to Rab6A-harboring 4 5 vesicles, also involved in Golgi-to-PM transport. However, Rab6A-TfR vesicles delivered TfR 4 6 directly to the PM, while in contrast, Rab7A was transiently associated to neosynthetic TfR-4 7 containing post-Golgi vesicles but dissociated before PM vesicle fusion. Together, our study 4 8
proposes the eRUSH as a powerful tool to further study the secretory pathway and reveals 4 9 1 0 0 formation of the TfR-Tf complex at the cell surface, the receptor is internalized by 1 0 1 clathrin-mediated endocytosis and delivered to endosomes. Inside these organelles, 1 0 2 TfR dissociates from its ligand and is recycled back to the cell surface. Studies progression (17, 18) . Indeed, cancer cells expressed a high amount of TfR at their cell 1 0 5 surface which makes it a significant anti-cancer target (19, 20) . Neosynthesized TfR arriving at the PM represents a minor fraction of the total TfR 1 0 7 pool expressed at the cell surface at steady state, and thus the pathway of newly 1 0 8
synthesized TfR is particularly difficult to investigate. In this study, we developed an 1 0 9 approach that combines the RUSH system with CRISPR/Cas9 gene editing that we 1 1 0 called "edited-RUSH" or "eRUSH". We employed eRUSH to investigate the molecular 1 1 1 mechanisms involved in the vesicular transport of neosynthesized TfR to the PM. The partners involved in this process. In particular, we highlighted that Rab7A, a small 1 1 5
Rab GTPase usually described as an endolysosomal marker, is required for efficient 1 1 6 arrival of neosynthesized TfR at the PM and was recruited to a subset of post-TGN 1 1 7
TfR-containing vesicles, suggesting that Rab7 may play a role in the anterograde 1 1 8 trafficking pathway of secretory vesicles. Generation and characterization of the TfR-eRUSH system.
The CRISPR/Cas9 strategy that we previously described (21) was used to engineer 1 2 2 the breast cancer-derived SUM159 cells to express endogenous TfR fused to the 1 2 3 streptavidin-binding peptide (SBP) and EGFP. Lentiviral transduction of a chimera 1 2 4 streptavidin-KDEL protein was performed to establish a stable cell line that retains 1 2 5 SBP-containing proteins in the ER (see (11) for original description of the RUSH 1 2 6 system) and the resulting TfR-eRUSH cells were subsequently characterized. As depicted in Figure 1A , SBP fused to EGFP was introduced in the genomic 1 2 8 sequence of TfR before its stop codon sequence. At the genomic DNA level, both 1 2 9 alleles were carrying an extra piece of DNA corresponding to the SBP-EGFP tag 1 3 0 ( Figure 1B) . At the protein level, almost no endogenous TfR was detected (at ≈ 84 1 3 1 kDa), while an upper band at ≈ 117 kDa appeared, corresponding to the expected 1 3 2 size of TfR-SBP-EGFP protein ( Figure S1A ). Of note, the molecular weights were 1 3 3 difficult to precisely assess as ladders from different brands were providing dissimilar 1 3 4 sizes for a given band. Using an anti-EGFP antibody, we could confirm that TfR-SBP-1 3 5 EGFP was indeed running at an apparent size of 117 kDa ( Figure S1B ). Depending 1 3 6 of the ladder used along our study, the TfR-eRUSH would appear as a band of either 1 3 7 ≈ 98 kDa or 117 kDa, although both would correspond to the TfR-eRUSH. From the immunoblot, it seemed that less TfR-SBP-EGFP proteins were expressed 1 3 9
in the edited cells than the endogenous TfR from WT cells. However, quantification of 1 4 0 the amount of proteins from bands of different sizes is not reliable due to different 1 4 1 protein transfer efficiency. Thus, an anti-TfR antibody staining on WT and TfR-1 4 2 eRUSH cells was performed and the mean fluorescence intensity of the TfR staining 1 4 3 was measured by flow cytometry. We found that TfR-eRUSH cells express less 1 4 4 endogenous TfR than their parental cell line ( Figure 1C ). Next, we carried out 3D confocal live cell imaging on TfR-eRUSH cells to determine 1 4 6
whether TfR-eRUSH could be efficiently retained in the ER. We observed that in 1 4 7 absence of biotin (0 min), TfR-eRUSH was retained in the ER ( Figure 1D , upper 1 4 8 panels and corresponding Movie S1). Two to six minutes after biotin addition, 1 4 9 vesicles were released from the ER to reach the Golgi apparatus. This trend was 1 5 0 successfully quantified by measuring the Pearson's correlation coefficient between eRUSH at the PM was measured by flow cytometry as in Figure 1E , and fold 3 0 6 enrichment of T15 over T0 ( Figure 5A ) was determined. As Rabs may affect other 3 0 7 cellular processes, the amount of TfR-eRUSH at steady-state was measured by flow 3 0 8 cytometry ( Figure S5 ). At T0-T15, silencing of Rab27A or Rab6A showed significant decrease of PM-3 1 0 associated TfR ( Figure 5A ) compared to the non-relevant siRNA control. These 3 1 1 findings were in agreement with the role of these Rabs in protein secretion 3 1 2 (13, 38, 39) , validating our approach. In contrast, Rab10 silencing had no detectable 3 1 3 effect on TfR trafficking to the PM, while we found it enriched in our proteomics 3 1 4 analysis ( Figure 2C ). Interestingly however, silencing of Rab7A showed a significant 3 1 5 inhibition of TfR-eRUSH arrival at the PM at T0-15. Although Rab7A is known for its 3 1 6 role in endocytic retrograde trafficking to late endosomes and lysosomes (34), this is 3 1 7 consistent with our AP-LC-MS/MS data ( Figure 2C ), further indicating that Rab7 To directly determine the fate of the Rab-harboring post-Golgi TfR-eRUSH vesicles, observed in the evanescent TIRF field. We monitored events during which Rab7- from 704 s to 736 s) before the two signals segregated again, followed by a TfR- These observations indicated that Rab7A vesicles are used as intermediate The trafficking kinetics of neosynthesized TfR-eRUSH was similar to the 3 5 0 overexpressed TfR in the RUSH system which was previously described to reach the 3 5 1 support PM-targeting of these vesicles ( Figure 5B ). Yet, the function of these vesicles 3 9 7 as compared to the Rab6-positive vesicles, remain to be determined.
9 8
A recent study by Chen and colleagues indicated that neosynthesized TfR was 3 9 9 sorted out with the Lamp1 protein in vesicles exiting the TGN (37). These vesicles 4 0 0 were devoid of the mannose-6P receptor (M6PR), which was used as a marker for 4 0 1
Golgi-to-endosome route (46). In our hands, we found that M6PR was absent of the secretory pathway remains to be fully determined. SUM159 cells were cultured in DMEM/F-12 GlutaMAX (GIBCO), supplemented with 5% 4 2 0 fetal bovine serum (FBS; Dominique Dutscher), 500 µg/ml penicillin-streptomycin (GIBCO), 1 4 2 1 µg/ml hydrocortisone (Sigma-Aldrich), 5 µg/ml insulin (Sigma-Aldrich), and 10 mM HEPES 4 2 2 (GIBCO) (complete medium). Cells were maintained at 37°C and 5% CO 2 . Gene editing of the SUM159 cells to fuse the GGSGGSGGS spacer, the SBP and 4 2 5 EGFP sequences to the C-ter of TfR a CRISPR/Cas9 strategy was used as 4 2 6 previously described (21, 48) . Briefly, three genetic tools were co-transfected using A clone that was edited on both alleles was further transduced with a lentiviral vector 4 3 9
coding the puromycine resistance gene and for the "hook" consisting of the To detect PM-localized TfR, 40 000 SUM159 cells were plated in 48 well plates and A pool of four different siRNAs for each of the 12 selected Rab proteins and a non- cherry-pick library (Dharmacon, Horizon Discovery; see details in Table S3 ). Forty based assay for PM-localized TfR described above was used for sample analysis. was centrifuged at 2 000 g for 15 min at 4°C. Supernatants were incubated for 2 h at washed five times with ice-cold PBS at 4°C before elution.
0 8
Mass spectrometry-based quantitative proteomics 5 0 9
Sample preparation
The immunoprecipitated samples were resuspended in Laemmli buffer and the 5 1 1 antibody-conjugated magnetic beads were removed. Protein concentration was 5 1 2 determined using the RC-DC protein assay (Bio-Rad) according to the carbonate and acetonitrile, reduced and alkylated before trypsin digestion (Promega).
1 7
The generated peptides were extracted with 60% acetonitrile in 0.1% formic acid 5 1 8
followed by a second extraction with 100% acetonitrile. Acetonitrile was evaporated 5 1 9
under vacuum and the peptides were resuspended in 16 µL of H20 and 0.1% formic 5 2 0 acid before nanoLC-MS/MS analysis. spectrometer (ThermoFisher Scientific) equipped with a nanoelectrospray ion source. AGC was set to 1.10 5 , and the maximal injection time was set to 100 ms. Peptides were fragmented in the HCD cell by higher-energy collisional dissociation with a 5 3 9
normalized collision energy set to 27. Peaks selected for fragmentation were Data interpretation 5 5 0
Raw MS data processing was performed using MaxQuant software (v 1.5.8.3 (49)). to 1, Carbamidomethyl (C) set as fixed modification, Acetyl (Protein N-term) and 5 5 7
Oxidation (M) set as variable modifications. False discovery rates (FDR) were 5 5 8 estimated based on the number of hits after searching a reverse database and was 5 5 9
set to 5% for both peptide spectrum matches (minimum length of seven amino acids)
and proteins. Data normalization and protein quantification was performed using the ratio count" of two. The "Match between runs" option was enabled using a 2 min time To be validated, proteins must be identified in all four replicates of one condition at 5 6 6
least. The imputation of the missing values and differential data analysis were 5 6 7
performed using the open-source ProStaR software (51). Two runs of imputation 5 6 8
were applied, the "SLSA" mode was applied for the POV (partially observed values) 5 6 9 and the "del quantile" for the MEC (missing in the entire condition). Pairwise calibration was performed using the pounds calibration method and the FDR 5 7 2
threshold was set at 5%. The complete proteomics dataset is available via
ProteomeXchange (52,53) with identifier PXD010576.
7 4
Gene ontology analysis 5 7 5
Gene set enrichment analysis (GSEA) was run on the protein lists found to be 5 7 6 significantly enriched at least 1.5 times in T0-T15, T0-T30 and T15-T30 using the their false-discovery rate (FDR). The Table S1 summarizes the relevant GO avidin. For the different eRUSH assays, cells were incubated at 5 min, 7 min, 12 min, with 4% PFA for 20 min at room temperature and were permeabilized for 15 min with were acquired with spinning disk confocal microscope at indicated time points post- containing TfR-eRUSH were isolated by immunoprecipitation using an anti-TfR compared to T0 (T0-T15) were investigated using the online GSEA online software. by LC-MS/MS (see Table S2 ), the fold enrichment and p values of the ones that were Actin was used as a loading control. Anti-TfR antibodies were used for visualization 1 0 0 7 and HMW protein marker was used for molecular weight estimation in (A). Anti-GFP 1 0 0 8 antibodies were used for visualization and LMW protein marker was used for 1 0 0 9 molecular weight estimation in (B). Table S3 . List of the target sequences used in the siRNA screen. 
